Cornea Project, a medical technology start-up and CataloniaBio & HealthTech member, has successfully closed an €872,000 round of investment through the Capital Cell platform. Its goal was to raise €700,000
The main investor in the round was Basque company AJL Ophthalmic. Pere del Campo, co-founder and CEO of Cornea Project, still holds the majority share.
These funds will be used to finish development of the firm's point of care platform for non-invasive diagnosis of eye conditions using biomarkers in the early stages, and for clinical validation. Initially, Cornea Project has focused on detecting keratoconus, a progressive, degenerative disease of the cornea that leads to blindness and vision loss.
Cornea Project has been awarded a patent in Europe and the United States to protect the only two biomarkers that can detect keratoconus in the early stages, with more than 90% specificity and sensitivity.
Photo: Pere del Campo, co-founder and CEO of Cornea Project - © Cornea Project
You may also be interested in:
Cornea Project opens €700,000 round with Capital Cell
Comments